CoChat

Amelioration of liver fibrosis with autologous macrophages induced by IL-34-based condition

Open access
Igarashi, Yuichi, Wada, Haruka, Muto, Masato, Sone, Ryohei, Hasegawa, Yoshinori, Seino, Ken-ichiro · 2025 · Inflammation and Regeneration

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Abstract

Background: For the treatment of liver fibrosis, several novel cell therapies have been proposed. Autologous macrophage therapy has been reported as one of the promising treatments. So far, most studies have used colony-stimulating factor 1 (CSF-1) to induce the differentiation of macrophage progenitor cells. The receptor for CSF-1, CSF-1R possesses another ligand, interleukin 34. However, the therapeutic capacity for liver fibrosis by interleukin 34-induced macrophages has not been evaluated. Methods: We have employed acute (bile duct ligation) and chronic (administration of carbon tetrachloride or thioacetamide) liver fibrosis models. Using these models, we evaluated the therapeutic capacity of macrophages induced by interleukin 34-based conditions. In most experiments, interleukin 4 was also added to the differentiation process to induce alternative-activated macrophages. As a mechanism analysis, we have examined liver inflammation and damage, the status of stellate cells, and the immunosuppressive capacity of the macrophages. Human macrophages were differentiated from CD14+ monocytes and analyzed. Results: In both acute and chronic liver damage experiments, interleukin 34-induced macrophages significantly ameliorated liver fibrosis. The addition of interleukin 4 to the differentiation process resulted in an increase of obtained macrophages and a bias to alternative activated macrophages (so-called M2). The alternative activated macrophages (M2-type) showed a reproducible therapeutic effect of liver fibrosis with a suppression of parameters of liver inflammation and damage, stellate cells, and T cell activation. Similar macrophages could be differentiated from human CD14+ monocytes in the presence of interleukin 34 plus interleukin 4, and a therapeutic effect was observed using a humanized mouse model. Conclusions: Interleukin 34-induced macrophages, particularly when additionally stimulated with interleukin 4, significantly ameliorated the liver fibrosis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s41232-025-00364-7

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 IL-34-induces Mf from bone marrow cells and inhibits liver fibrosis. A, B Sirius red staining of liver sections from C57BL/6 J mice with liver fibrosis induced by CCl4 (A) and BDL (B). Similar results were obtained from two independent experiments. A Saline or Mfs were intravenously injected at 8 weeks, and at 12 weeks liver samples were obtained (n = 6 each group). B Saline or Mfs were intravenously injected at 10 days, and at 14 days liver samples were obtained (n = 6 each group). Scale bar indicates 200 μm. The bar graphs represent the quantified Sirius red-positive area ratio (mean ± SEM). *P < 0.05; ***P < 0.001. C Appearance of the Mfs. Scale bar indicates 100 μm. D Comparison of mRNA expressions of CSF-1 and IL-34 Mfs
Fig. 1 IL-34-induces Mf from bone marrow cells and inhibits liver fibrosis. A, B Sirius red staining of liver sections from C57BL/6 J mice with liver fibrosis induced by CCl4 (A) and BDL (B). Similar results were obtained from two independent experiments. A Saline or Mfs were intravenously injected at 8 weeks, and at 12 weeks liver samples were obtained (n = 6 each group). B Saline or Mfs were intravenously injected at 10 days, and at 14 days liver samples were obtained (n = 6 each group). Scale bar indicates 200 μm. The bar graphs represent the quantified Sirius red-positive area ratio (mean ± SEM). *P < 0.05; ***P < 0.001. C Appearance of the Mfs. Scale bar indicates 100 μm. D Comparison of mRNA expressions of CSF-1 and IL-34 MfsCC BY · PubMed Central
Fig. 2 IL-34 + IL-4-induced Mf exhibits M2-biased, immunosuppressive properties. A Comparison of mRNA expression levels of Mfs induced by each cytokine, shown as fragments per kilobase of exon per million mapped reads (FPKM). B Flow cytometry analyses. Colored histograms showing cells expressing the indicated surface proteins. White histograms showing the isotype control staining. Similar results were obtained from more than two independent experiments. C Cell viability of Mfs detected by MTT assay. ***P < 0.001
Fig. 2 IL-34 + IL-4-induced Mf exhibits M2-biased, immunosuppressive properties. A Comparison of mRNA expression levels of Mfs induced by each cytokine, shown as fragments per kilobase of exon per million mapped reads (FPKM). B Flow cytometry analyses. Colored histograms showing cells expressing the indicated surface proteins. White histograms showing the isotype control staining. Similar results were obtained from more than two independent experiments. C Cell viability of Mfs detected by MTT assay. ***P < 0.001CC BY · PubMed Central
Fig. 3 IL-34 + IL-4-induced Mf prevents both acute and chronic liver fibrosis models. A Sirius red staining of liver sections from BDL-induced liver fibrosis mice (n > 6 each group). The timing of treatment and sample collection was the same as Fig. 1B. Scale bar indicates 200 μm. B Sirius red staining of liver sections from TAA-induced liver fibrosis mice (n > 6 each group). Saline or Mfs were intravenously injected at 6 weeks, and at 10 weeks liver samples were obtained. Scale bar indicates 200 μm. Bar graphs show the quantification of Sirius red-positive area ratios (mean ± SEM). Similar results were obtained from two independent experiments. C AST and ALT levels in the sera of the TAA model (mean ± SEM). Blood samples were collected before (at 4 weeks) and after (at 10 weeks) the Mf treatment. D TUNEL staining of the liver samples at 10 weeks (TAA model). Bar graphs show the TUNEL-positive cells. Bar graphs show the cell counts of TUNEL-positive cells (mean ± SEM). E, F Immunohistochemistry of liver sections for COL1A (C) and α-SMA (D) expressions in the TAA model. Bar graphs show the quantification of immunostained positive area ratios (mean ± SEM). * P < 0.05; **P < 0.01
Fig. 3 IL-34 + IL-4-induced Mf prevents both acute and chronic liver fibrosis models. A Sirius red staining of liver sections from BDL-induced liver fibrosis mice (n > 6 each group). The timing of treatment and sample collection was the same as Fig. 1B. Scale bar indicates 200 μm. B Sirius red staining of liver sections from TAA-induced liver fibrosis mice (n > 6 each group). Saline or Mfs were intravenously injected at 6 weeks, and at 10 weeks liver samples were obtained. Scale bar indicates 200 μm. Bar graphs show the quantification of Sirius red-positive area ratios (mean ± SEM). Similar results were obtained from two independent experiments. C AST and ALT levels in the sera of the TAA model (mean ± SEM). Blood samples were collected before (at 4 weeks) and after (at 10 weeks) the Mf treatment. D TUNEL staining of the liver samples at 10 weeks (TAA model). Bar graphs show the TUNEL-positive cells. Bar graphs show the cell counts of TUNEL-positive cells (mean ± SEM). E, F Immunohistochemistry of liver sections for COL1A (C) and α-SMA (D) expressions in the TAA model. Bar graphs show the quantification of immunostained positive area ratios (mean ± SEM). * P < 0.05; **P < 0.01CC BY · PubMed Central
Fig. 4 IL-34 + IL-4-induced Mf suppresses T cell reponses. A Gating strategy of the flow cytometry analysis. B IL-34 + IL-4 Mfs were co-cultured with CFSE-stained T cells, separated from spleen cells by magnetic cell sorting, and stimulated with anti-CD3 and CD28 antibodies for 4 days. The histogram shows CFSE fluorescence intensity for cells gated on CD4- and CD8-positive cells. Culture conditions include stimulated T cells without co-culture (stimulated; green), T cells without proliferation stimulation (non-stimulated; gray), and co-cultured with Mf in the presence of control IgG (control; red) or anti-PD-L1 and anti-PD-L2 antibodies (Abs; blue). Similar results were obtained from two independent experiments. C, D Immunohistochemistry of CD8- or CD69-positive cells in the liver sections from TAA-induced liver fibrosis mice. Bar graphs show the quantification of immunostained cell counts (mean ± SEM, n = 3 each group). ***P < 0.001
Fig. 4 IL-34 + IL-4-induced Mf suppresses T cell reponses. A Gating strategy of the flow cytometry analysis. B IL-34 + IL-4 Mfs were co-cultured with CFSE-stained T cells, separated from spleen cells by magnetic cell sorting, and stimulated with anti-CD3 and CD28 antibodies for 4 days. The histogram shows CFSE fluorescence intensity for cells gated on CD4- and CD8-positive cells. Culture conditions include stimulated T cells without co-culture (stimulated; green), T cells without proliferation stimulation (non-stimulated; gray), and co-cultured with Mf in the presence of control IgG (control; red) or anti-PD-L1 and anti-PD-L2 antibodies (Abs; blue). Similar results were obtained from two independent experiments. C, D Immunohistochemistry of CD8- or CD69-positive cells in the liver sections from TAA-induced liver fibrosis mice. Bar graphs show the quantification of immunostained cell counts (mean ± SEM, n = 3 each group). ***P < 0.001CC BY · PubMed Central
Fig. 5 Phenotype and function of human IL-34 + IL-4-induced Mf. A Flow cytometry analyses. Green histograms showing cells expressing the indicated surface proteins. Gray histograms showing the isotype control staining. B Human IL-34 + IL-4 Mfs were co-cultured with CFSE-stained T cells stimulated with anti-CD3 and CD28 antibodies for 4 days. The histogram shows CFSE fluorescence intensity for cells gated on CD4 and CD8. C Sirius red staining of liver sections from human PBMCs-injected NSG mice (n = 3 each group). Saline or IL-34 + IL-4 Mfs were intravenously injected at 4 weeks, and at 8 weeks liver samples were obtained. Scale bar indicates 200 μm. Bar graphs show the quantification of Sirius red-positive area ratios (mean ± SEM). D AST and ALT levels in the sera (mean ± SEM). Blood samples were collected before (at 4 weeks) and after (at 8 weeks) the Mf treatment. E, F TUNEL or CD8 staining of the liver samples. Bar graphs show the counts of positive cells (mean ± SEM). *P < 0.05
Fig. 5 Phenotype and function of human IL-34 + IL-4-induced Mf. A Flow cytometry analyses. Green histograms showing cells expressing the indicated surface proteins. Gray histograms showing the isotype control staining. B Human IL-34 + IL-4 Mfs were co-cultured with CFSE-stained T cells stimulated with anti-CD3 and CD28 antibodies for 4 days. The histogram shows CFSE fluorescence intensity for cells gated on CD4 and CD8. C Sirius red staining of liver sections from human PBMCs-injected NSG mice (n = 3 each group). Saline or IL-34 + IL-4 Mfs were intravenously injected at 4 weeks, and at 8 weeks liver samples were obtained. Scale bar indicates 200 μm. Bar graphs show the quantification of Sirius red-positive area ratios (mean ± SEM). D AST and ALT levels in the sera (mean ± SEM). Blood samples were collected before (at 4 weeks) and after (at 8 weeks) the Mf treatment. E, F TUNEL or CD8 staining of the liver samples. Bar graphs show the counts of positive cells (mean ± SEM). *P < 0.05CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 31 references

Cited by

See all 5

Metadata

Authors
Igarashi, Y., Wada, H., Muto, M., Sone, R., Hasegawa, Y., & Seino, K.-I.
Affiliations
  • Hokkaido University (JP)
  • Medinet Co., Ltd. (Japan) (JP)
  • Kazusa DNA Research Institute (JP)
Corresponding author
Seino, Ken-ichiro
Venue
Inflammation and Regeneration
Published
2025-01-24
Volume
45
Issue
1
Pages
2-2
ISSN
  • 1346-8022 (ISSN-L)
  • 1880-8190
OpenAlex
W4406807889
Cited by
5
References
30
Citations by year
2026: 1 · 2025: 4
FWCI
2.81
Type
journal article
Language
en
Open access
Licence
Locations
  • Inflammation and Regeneration (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
AMED (JP24fk0210117)
Topics
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
Keywords
liver fibrosis, IL-34, IL-4, alternative activated macrophages, M2 macrophages, macrophage differentiation, CD14+ monocytes, hepatic stellate cells, liver inflammation, T cell activation, bile duct ligation, carbon tetrachloride, thioacetamide, humanized mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Amelioration of liver fibrosis with autologous macrophages induced by IL-34-based condition. https://app.cochat.ai/papers/10.1186/s41232-025-00364-7
The paper
Igarashi, Y., Wada, H., Muto, M., Sone, R., Hasegawa, Y., & Seino, K.-I. (2025). Amelioration of liver fibrosis with autologous macrophages induced by IL-34-based condition. Inflammation and Regeneration. https://doi.org/10.1186/s41232-025-00364-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.